India Caps Margins on 137 Cancer Medicines, With Steep Cuts but Uneven Relief

New prices begin November 9, but savings depend on the medicine

India's National Pharmaceutical Pricing Authority (NPPA) has ordered a 30% cap on trade margins for 137 cancer medicines from November 9, 2026, bringing sharp reductions for some treatments while leaving several expensive brands unchanged. One chemotherapy injection, Samtepa, will fall from Rs 80,071.86 to Rs 7,150.33 for a vial containing 100 mg.

The regulator issued the order on October 17 under Paragraph 19 of the Drugs (Prices Control) Order, 2013, which permits intervention in the public interest. The measure targets the difference between prices charged to distributors or stockists and the maximum retail price, or MRP, billed to patients.

The government initially described potential reductions of up to 70%. Subsequent company price lists show a wider range: some products have cuts exceeding 90%, while others have no reduction. Palbopro, a breast cancer medicine containing palbociclib, falls 93.3%, from Rs 40,421.33 to Rs 2,720 for 21 capsules containing 125 mg each.

NPPA estimates put annual savings for patients at Rs 2,500 crore to Rs 3,500 crore, equivalent to Rs 25 billion to Rs 35 billion. Several government statements have used the lower estimate of Rs 2,500 crore. Those are projected savings across the market; a family's benefit will depend on the prescribed brand, dose and treatment schedule.

The central limit is straightforward: the order controls distribution margins rather than directly fixing the manufacturer's starting price. Patients buying a medicine with a large distribution markup may receive substantial relief. Those prescribed an expensive product whose starting price remains high may see little change.

For families paying for repeated treatment, the difference can be considerable. A lower price on every vial or monthly pack can reduce recurring bills, but tests, hospital care and other treatment expenses remain separate costs.

How the 30% margin works

The cap applies to the MRP excluding goods and services tax. A trade margin is the share of the final price retained between the distributor or stockist purchase price and the price charged to the patient.

A simple example explains the calculation. If the relevant purchase price is Rs 700, the permitted selling price before tax would be Rs 1,000. The Rs 300 difference is 30% of that final price. Expressed instead as a markup on Rs 700, it is 42.86%.

The revised calculations use prices charged to stockists or distributors in March 2026. Manufacturers must submit updated price information within seven days of Gazette publication, including information for products whose MRPs remain unchanged.

The academic journal BMJ's analysis of the cap describes the intervention as a limit on distributor and retailer margins. It says NPPA's October market analysis found average markups of about 170% on cancer medicines outside the regular ceiling price system, reaching 700% or more in some cases.

A 30% margin cap therefore produces different reductions depending on the starting figures. A product with a very large gap between its distribution price and MRP has more room for a cut than one whose high retail price mainly reflects the manufacturer's charge.

Which treatments are covered?

The 137 medicines are described as non-scheduled, meaning they sit outside the routine ceiling prices applied to medicines listed in Schedule I of the Drugs (Prices Control) Order. The intervention covers listed medicines across strengths and dosage forms, including combinations, branded and generic products, imports and medicines protected by patents.

The list spans chemotherapy, targeted treatments, hormonal medicines, immunotherapies and supportive medicines. Named products include pembrolizumab, nivolumab, durvalumab, osimertinib, olaparib, denosumab, topotecan and bevacizumab. Their uses extend across breast, prostate, lung, colorectal, ovarian and cervical cancers, among others.

Some medicines address complications associated with cancer or its treatment. Pegfilgrastim helps prevent a shortage of infection fighting white blood cells after chemotherapy. Denosumab is used in managing bone complications, including in some patients with breast or prostate cancer.

India also has an existing ceiling price system covering 63 cancer medicines under the National List of Essential Medicines 2022. NPPA estimates the cancer medicine market at about Rs 12,500 crore annually, with scheduled medicines accounting for roughly Rs 2,250 crore and non-scheduled products for more than Rs 10,250 crore. Most spending therefore falls in the latter category.

Where the largest reductions appear

Samtepa's revised price represents a saving of Rs 72,921.53 per vial, or about 91.1%. Thiotepa, its active ingredient, is a chemotherapy medicine used in settings including preparation for stem cell transplantation. The final saving over a treatment course depends on the amount prescribed.

Other substantial reductions span injections and oral medicines:

• Hertumab, containing pertuzumab for certain breast cancers, falls from Rs 94,951 to Rs 30,593 per vial, a reduction of about 68%.
• Ivzumab, containing bevacizumab, falls from Rs 69,852.12 to Rs 13,512 for an injection containing 400 mg.
• Cizumab, another bevacizumab brand containing 400 mg, falls from Rs 57,816 to Rs 10,211, a reduction exceeding 82%.
• Brcaone, an olaparib pack containing tablets of 150 mg, falls from Rs 46,364.05 to Rs 11,573.68.
• Abirat, containing abiraterone acetate for prostate cancer, falls from Rs 36,088.81 to Rs 4,064.48 for a bottle of 120 tablets containing 250 mg each.
• Anastrozole sold by RPG Life Sciences falls from Rs 695.76 to Rs 73 for 10 tablets.

The figures also reveal different outcomes for brands containing the same medicine. Roche's Avastin containing 400 mg of bevacizumab remains at about Rs 123,506, while Reliance's competing BevaciRel falls to Rs 12,668, a reduction of about 83%.

Doctors choose treatment according to the cancer, the patient's condition and the medicine's approved use. Brand prices can help families understand the bill, while decisions about a suitable alternative remain part of clinical care.

Why some expensive medicines remain unchanged

Keytruda, the pembrolizumab immunotherapy used for several cancers, remains at Rs 216,000 for a vial containing 100 mg. Ribociclib, a targeted breast cancer treatment, remains at Rs 24,435 for 21 tablets containing 200 mg each.

The Third World Network (TWN), which works on access to medicines, found that all 53 listed entries from Eli Lilly, Novartis, Roche and AstraZeneca remained unchanged. In contrast, every listed entry from Intas, Zydus, Samarth Life Sciences and RPG Life Sciences received a cut, with average reductions across those companies ranging from 36% to 71%.

K M Gopakumar, co-convenor of the Working Group on Access to Medicines and Treatments, said competition is central to whether the measure reaches expensive patented products:

The list of revised MRP confirms our view that trade margin rationalisation is unlikely to affect the prices of patent drug in the absence of competition as seen among generic manufacturers,

A patent can limit competing versions of a medicine for a period. If the manufacturer's initial price is already high, reducing the distribution margin leaves that major component of the bill in place. Gopakumar has argued for using existing patent law provisions, including compulsory licensing, to address such costs. Compulsory licensing allows another producer to make a patented product under legally specified conditions.

What the price lists show

The October 28 revised list was described as covering 543 formulations, meaning different brands, strengths and packs of the 137 medicines; TWN's analysis used 643 brand, strength and pack entries, while another published tally cited nearly 900 brands. A common explanation reconciling those totals has not been published.

Within the count of 543 formulations, 146 had unchanged prices and another 21 received reductions of less than Rs 100. Together, those 167 entries account for about 31% of that list. The average price change across all 543 was just over Rs 5,000.

TWN calculated an average percentage reduction of about 38% across its list, with 124 entries falling by more than 70%. An average percentage cut and an average saving in rupees measure different things: a large percentage reduction on a cheap medicine can save less money than a smaller percentage reduction on an expensive injection.

The pattern makes the prescribed product more useful to an individual family than a headline average. Raziuddin Khwaja, a consultant in medical oncology at the Head and Neck Cancer Institute of India, explained how treatment needs shape the benefit:

What a patient gains will depend on their cancer type, stage and prescribed regimen.

Why the 2019 experience matters

NPPA first tested trade margin rationalisation on 42 cancer medicines in 2019. That exercise reduced MRPs across 526 brands, with some cuts reaching 90%, and reportedly generated annual savings of Rs 984 crore. Thirty four medicines from that exercise appear in the latest round.

The All India Drug Action Network (AIDAN) compared 50 medicine products covered in both rounds and found that 38 had risen in price after the earlier intervention. Before the latest adjustment, 45 had markups exceeding the earlier threshold of about 42.8%. AIDAN estimated Cizumab's markup at approximately 709%.

AIDAN argues that periodic price resets leave room for margins to grow again between interventions. Non-scheduled medicines can generally receive annual price increases of up to 10%, and the network has called for continuing checks on actual transaction prices.

Jan Swasthya Abhiyan India, a public health coalition, welcomed the intervention while calling for sustained oversight:

A one-time exercise that brings down prices, without establishing continuing obligations and independent monitoring, cannot prevent excessive margins from returning,

The latest order follows renewed judicial scrutiny. Its key dates show how the intervention developed:

• September 2026: The Supreme Court questioned large medicine price gaps, including a product supplied to a retailer for about Rs 2,700 with an MRP of Rs 27,000.
• October 17: NPPA notified the new trade margin intervention for 137 medicines.
• October 27: The Supreme Court asked about broader medicine price controls and reserved its order in Kishan Chand Jain v. EMRB.
• October 28: A revised list of company prices was released.
• November 9: The revised prices take effect.

The broader court case concerns how far price regulation should extend beyond selected medicines. No date for the reserved judgment was given.

Patients receiving assistance may benefit differently

Manufacturer funded patient assistance programmes, or PAPs, supply free or discounted medicines to eligible patients. Some reduce spending on expensive immunotherapies and targeted treatments by 30% to 60%, although eligibility, paperwork and treatment arrangements vary.

Dr Tanvi Singh, a medical oncologist at MOC Cancer Care on Pusa Road in New Delhi, said people already receiving substantial assistance may see little additional saving:

The trade-margin cap is unlikely to reduce costs for patients enrolled in PAPs, because their medicines are already being provided free or at heavily discounted rates,

Free quantities supplied through qualifying programmes are excluded from the price calculations. AIDAN co-convenor Malini Aisola argues that excluding those quantities understates trade margins because free supplies change the effective cost of the medicines distributed.

NPPA requires manufacturers seeking the exemption to retain records covering patient identity, diagnosis, dosage and medicines received and consumed. The regulator can request further details, conduct audits or inspections, and use verification by outside agencies.

Hospital sales are especially important to enforcement. Industry estimates place nearly 70% of cancer medicine sales in hospitals, while retail rankings leave out institutional supplies and assistance programmes. Pharmarack's retail data for September 2026 identified only three of the 10 leading cancer medicines as covered by the new margin order: bevacizumab, nivolumab and abiraterone acetate.

Enforcement and the rest of the treatment bill

Manufacturers must publish revised price lists on their websites and inform hospitals and retailers. Pharmacies and hospitals must charge the applicable revised prices from November 9 and display updated lists. Patients can check listed prices through the Pharma Sahi Daam app and NPPA's website.

Assam's Drugs Control Administration has announced a statewide inspection drive lasting 90 days. Its directive covers pharmacies, hospital dispensaries, stockists and distributors, and cites the price display requirement under Paragraph 25(3) of the Drugs (Prices Control) Order. Violations can prompt action under that order and the Essential Commodities Act, 1955.

The Assam administration made its instruction explicit:

Immediate and strict compliance is mandated,

Patients still face expenses beyond medicines: scans, laboratory tests, surgery, radiation, admission, supportive treatment and repeated follow up. Travel, accommodation and lost earnings add to the burden for families seeking treatment far from home.

Dr Harit Chaturvedi, chief executive officer of Apollo Hospitals' Oncology Department, has said affordability rules also need to account for the costs of technology, operations and advanced care. Public financing through Ayushman Bharat-PM-JAY, suitable treatment packages and research into effective, affordable therapies are other parts of reducing the total bill.

The concrete test from November 9 is whether hospitals and pharmacies apply the revised prices to the medicines patients actually receive. Longer term affordability will also depend on sustained price monitoring, access to assistance and insurance, and the cost of completing the full course of care.

Key Points

• NPPA capped trade margins on 137 non-scheduled cancer medicines at 30% of MRP excluding tax, effective November 9, 2026.
• Some listed products fall by more than 90%, while several expensive brands remain unchanged.
• The measure limits distribution margins rather than directly fixing manufacturers' starting prices.
• Patients already receiving free or heavily discounted medicines may see smaller additional savings.
• Assam announced inspections lasting 90 days, and hospitals and pharmacies must display revised prices.
• Total cancer treatment costs still include diagnostics, hospital care, supportive treatment and travel.